<h1>Paper Summary</h1>

<!--META_START-->

<p>Title: Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer  </p>

<p>Authors: Jaana Oikkonen, Kaiyang Zhang, Liina Salminen, Ingrid Schulman, Kari Lavikka, Noora Andersson, Erika Ojanperä, Sakari Hietanen, Seija Grenman, Rainer Lehtonen, Kaisa Huhtinen, Olli Carpén, Johanna Hynninen, Anniina Färkkilä, Sampsa Hautaniemi  </p>

<p>DOI: https://doi.org/10.1200/PO.18.00343  </p>

<p>Year: 2019  </p>

<p>Publication Type: Journal  </p>

<p>Discipline/Domain: Oncology / Precision Medicine  </p>

<p>Subdomain/Topic: Circulating Tumor DNA (ctDNA) in High-Grade Serous Ovarian Cancer (HGSOC)  </p>

<p>Eligibility: Eligible  </p>

<p>Overall Relevance Score: 90  </p>

<p>Operationalization Score: 95  </p>

<p>Contains Definition of Actionability: Yes (implicit, clinically oriented)  </p>

<p>Contains Systematic Features/Dimensions: Yes  </p>

<p>Contains Explainability: Yes  </p>

<p>Contains Interpretability: Yes  </p>

<p>Contains Framework/Model: Yes (workflow pipeline)  </p>

<p>Operationalization Present: Yes  </p>

<p>Primary Methodology: Mixed Methods (prospective clinical cohort, bioinformatics pipeline)  </p>

<p>Study Context: Clinical workflow for longitudinal ctDNA analysis to guide treatment in HGSOC  </p>

<p>Geographic/Institutional Context: Turku University Hospital &amp; University of Helsinki, Finland  </p>

<p>Target Users/Stakeholders: Oncologists, molecular tumor boards, translational cancer researchers  </p>

<p>Primary Contribution Type: Clinical proof-of-concept &amp; open-source workflow  </p>

<p>CL: Yes  </p>

<p>CR: Yes  </p>

<p>FE: Yes  </p>

<p>TI: Yes  </p>

<p>EX: Yes  </p>

<p>GA: Yes  </p>

<p>Reason if Not Eligible: N/A  </p>

<!--META_END-->

<p><strong>Title:</strong>  </p>

<p>Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer  </p>

<p><strong>Authors:</strong>  </p>

<p>Jaana Oikkonen, Kaiyang Zhang, Liina Salminen, Ingrid Schulman, Kari Lavikka, Noora Andersson, Erika Ojanperä, Sakari Hietanen, Seija Grenman, Rainer Lehtonen, Kaisa Huhtinen, Olli Carpén, Johanna Hynninen, Anniina Färkkilä, Sampsa Hautaniemi  </p>

<p><strong>DOI:</strong>  </p>

<p>https://doi.org/10.1200/PO.18.00343  </p>

<p><strong>Year:</strong>  </p>

<p>2019  </p>

<p><strong>Publication Type:</strong>  </p>

<p>Journal  </p>

<p><strong>Discipline/Domain:</strong>  </p>

<p>Oncology / Precision Medicine  </p>

<p><strong>Subdomain/Topic:</strong>  </p>

<p>ctDNA analysis in high-grade serous ovarian cancer (HGSOC)  </p>

<p><strong>Contextual Background:</strong>  </p>

<p>The study addresses the challenge of guiding treatment in metastatic solid cancers, particularly HGSOC, where tissue sampling is invasive and may not capture tumor heterogeneity. It develops an open-source ctDNA workflow to longitudinally monitor genomic alterations and guide therapy.  </p>

<p><strong>Geographic/Institutional Context:</strong>  </p>

<p>University of Helsinki &amp; Turku University Hospital, Finland  </p>

<p><strong>Target Users/Stakeholders:</strong>  </p>

<p>Oncologists, molecular tumor boards, translational researchers, precision medicine programs  </p>

<p><strong>Primary Methodology:</strong>  </p>

<p>Mixed methods — prospective clinical cohort of 12 HGSOC patients (78 plasma samples, 21 tissue samples) + bioinformatics and translational knowledgebase integration  </p>

<p><strong>Primary Contribution Type:</strong>  </p>

<p>Clinical proof-of-concept and open-source workflow for actionable ctDNA detection  </p>

<hr />

<h2>General Summary of the Paper</h2>

<p>This study presents a clinical and bioinformatics workflow for detecting clinically actionable alterations in HGSOC using longitudinal ctDNA sampling. The pipeline integrates &gt;500-gene targeted sequencing, a ctDNA-specific bioinformatics pipeline, and the Translational Oncology Knowledgebase to prioritize alterations based on ESCAT tiers. Across 12 patients, ctDNA mutations and CNAs showed high concordance with tumor tissue findings. Clinically actionable alterations were identified in 58% of patients, guiding therapy in one platinum-resistant case (ERBB2 amplification → trastuzumab + chemo) with significant tumor regression and CA-125 normalization. The workflow demonstrates early detection of poor responders and suggests potential for personalized treatment adaptation.</p>

<hr />

<h2>Eligibility</h2>

<p>Eligible for inclusion: <strong>Yes</strong>  </p>

<hr />

<h2>How Actionability is Understood</h2>

<p>Implicitly defined as the presence of genomic alterations in ctDNA that can be linked to existing therapies, ranked by clinical evidence (ESCAT tiers), and used to guide treatment decisions in real time. Actionability requires reliable detection, clinical relevance, and therapeutic linkage.</p>

<blockquote>
  <p>“Potentially clinically actionable alterations were validated… classified as most prominent (ESCAT… Scale for Clinical Actionability of Molecular Targets)” (p. 3)  </p>
</blockquote>

<blockquote>
  <p>“The provided approach allows the selection of treatment options that target subclones that persist during therapy.” (p. 2)  </p>
</blockquote>

<hr />

<h2>What Makes Something Actionable</h2>

<ul>
<li><p>Direct association with existing or investigational therapies  </p></li>
<li><p>Sufficient evidence of clinical relevance (ESCAT ranking)  </p></li>
<li><p>Persistence in tumor subclones during treatment  </p></li>
<li><p>Validation in tumor tissue (IHC/ISH)  </p></li>
<li><p>Concordance with patient’s mutational profile and disease context  </p></li>
</ul>

<hr />

<h2>How Actionability is Achieved / Operationalized</h2>

<ul>
<li><p><strong>Framework/Approach Name(s):</strong> Clinical ctDNA workflow integrating sequencing, bioinformatics pipeline, and Translational Oncology Knowledgebase  </p></li>
<li><p><strong>Methods/Levers:</strong> &gt;500-gene targeted panel sequencing, variant/CNA calling, filtering, prioritization via knowledgebase, validation via IHC/ISH  </p></li>
<li><p><strong>Operational Steps / Workflow:</strong> Longitudinal plasma sampling → sequencing → bioinformatics filtering → therapeutic matching (ESCAT) → validation → clinical decision  </p></li>
<li><p><strong>Data &amp; Measures:</strong> VAF dynamics, mutation counts, CNA ratios, CA-125 levels  </p></li>
<li><p><strong>Implementation Context:</strong> Prospective monitoring before, during, after chemotherapy in HGSOC  </p></li>
</ul>

<blockquote>
  <p>“Longitudinal ctDNA sampling can be used to detect response… and identify clinically applicable mutations and copy number alterations.” (p. 2)  </p>
</blockquote>

<hr />

<h2>Dimensions and Attributes of Actionability (Authors’ Perspective)</h2>

<ul>
<li><p><strong>CL (Clarity):</strong> Yes — clear link between detected alteration and therapeutic relevance (ESCAT criteria).  </p></li>
<li><p><strong>CR (Contextual Relevance):</strong> Yes — therapy matching based on patient-specific ctDNA profile.  </p></li>
<li><p><strong>FE (Feasibility):</strong> Yes — minimally invasive sampling, open-source tools.  </p></li>
<li><p><strong>TI (Timeliness):</strong> Yes — early detection of poor responders after 1–2 chemo cycles.  </p></li>
<li><p><strong>EX (Explainability):</strong> Yes — biological pathway context and evidence level for each alteration.  </p></li>
<li><p><strong>GA (Goal Alignment):</strong> Yes — aligns with goal of improving survival in HGSOC by targeting resistant subclones.  </p></li>
<li><p><strong>Other Dimensions Named by Authors:</strong> Concordance with tumor tissue; evidence-based prioritization (ESCAT).  </p></li>
</ul>

<hr />

<h2>Theoretical or Conceptual Foundations</h2>

<ul>
<li><p>ESCAT (ESMO Scale for Clinical Actionability of Molecular Targets)  </p></li>
<li><p>Concepts from precision oncology: mTOR, HR deficiency, EGFR pathway targeting  </p></li>
<li><p>Longitudinal biomarker monitoring  </p></li>
</ul>

<hr />

<h2>Indicators or Metrics for Actionability</h2>

<ul>
<li><p>Variant Allele Frequency (VAF) trends  </p></li>
<li><p>CNA ratios  </p></li>
<li><p>CA-125 tumor marker correlation  </p></li>
<li><p>ESCAT evidence tier assignment  </p></li>
</ul>

<hr />

<h2>Barriers and Enablers to Actionability</h2>

<ul>
<li><p><strong>Barriers:</strong> Low VAF subclonal mutations, ctDNA heterogeneity, validation requirements, therapy availability  </p></li>
<li><p><strong>Enablers:</strong> Open-source pipeline, integration with knowledgebase, high plasma-tumor concordance, minimally invasive sampling  </p></li>
</ul>

<hr />

<h2>Relation to Existing Literature</h2>

<p>Builds on prior ctDNA monitoring studies (e.g., TP53 tracking in HGSOC) but extends to broad-panel actionable mutation detection and real-time therapeutic adaptation.</p>

<hr />

<h2>Summary</h2>

<p>This paper delivers a robust, clinically relevant framework for using longitudinal ctDNA profiling to guide therapy in HGSOC. Actionability is framed as the ability to detect and therapeutically match validated genomic alterations in a patient’s ctDNA profile, with emphasis on ESCAT evidence ranking and early detection of resistance. The study operationalizes this via a &gt;500-gene targeted sequencing panel, tailored bioinformatics pipeline, and knowledgebase integration, validated in a prospective cohort. The method not only identifies actionable alterations in over half of patients but also demonstrates a real-world therapy change with significant clinical benefit. The framework’s open-source nature enhances feasibility for clinical adoption.</p>

<hr />

<h2>Scores</h2>

<ul>
<li><p><strong>Overall Relevance Score:</strong> 90 — Clear conceptualization of clinical actionability and explicit criteria for linking genomic findings to therapies.  </p></li>
<li><p><strong>Operationalization Score:</strong> 95 — Comprehensive, step-by-step clinical workflow integrating sampling, analysis, prioritization, and validation.  </p></li>
</ul>

<hr />

<h2>Supporting Quotes from the Paper</h2>

<ul>
<li><p>“We identified high-confidence, potentially clinically actionable mutations or CNAs in seven patients (58%).” (p. 6)  </p></li>
<li><p>“The provided approach allows the selection of treatment options that target subclones that persist during therapy.” (p. 2)  </p></li>
<li><p>“Treatment… was changed on the basis of detection of ERBB2 amplification… followed by significant tumor shrinkage.” (p. 1)  </p></li>
<li><p>“Longitudinal ctDNA sampling can be used… to identify poor-responding patients after first cycles of chemotherapy.” (p. 1)  </p></li>
</ul>

<hr />

<h2>Actionability References to Other Papers</h2>

<ul>
<li><p>ESCAT framework: Mateo et al., 2018  </p></li>
<li><p>TP53 monitoring in HGSOC: Parkinson et al., 2016  </p></li>
<li><p>Pathway-specific targeting references for mTOR, HR deficiency, EGFR, CDK alterations</p></li>
</ul>
